Literature DB >> 17712998

Reduced number and function of CD4+CD25highFoxP3+ regulatory T cells in patients with systemic lupus erythematosus.

Elena Yu Lyssuk1, Anna V Torgashina, Sergey K Soloviev, Evgeny L Nassonov, Svetlana N Bykovskaia.   

Abstract

CD4+CD25+ regulatory T cells (Tregs) play an important role in maintaining tolerance to self-antigens controlling occurrence of autoimmune diseases. Recently, it has been shown that the transcription factor forkhead box P3 (FoxP3) is specifically expressed on CD4+CD25+ T cells. FoxP3 has been described as the master control gene for the development and function of Tregs. We characterized CD4+CD25+CTLA-4+FoxP3+ T cells in 43 patients with systemic lupus erythematosus (SLE). Twenty of them comprised a group of newly admitted patients with the first manifestations of the disease, and the second group included patients that were treated with cytostatics and steroids. The results revealed a significant decrease in CD4+CD25+ and CD4+CD25high T cells numbers in patients from group I compared with control and group II patients. Coexpression of FoxP3 on CD4+CD25+ T cells was significantly reduced in both groups regardless the therapy. The ability of Tregs to suppress proliferation of autologous CD8+ and CD4+ T cells was significantly reduced in both groups of patients compared to healthy donors. Our data revealed impaired production of Tregs in SLE patients that can be partly restored by conventional treatments.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17712998

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  49 in total

Review 1.  Pathogenic immunity in systemic lupus erythematosus and atherosclerosis: common mechanisms and possible targets for intervention.

Authors:  M Wigren; J Nilsson; M J Kaplan
Journal:  J Intern Med       Date:  2015-11       Impact factor: 8.989

Review 2.  Natural regulatory T cells in autoimmunity.

Authors:  Elaine V Lourenço; Antonio La Cava
Journal:  Autoimmunity       Date:  2010-11-23       Impact factor: 2.815

Review 3.  The role of CD4+CD25+ T regulatory cells in autoimmune diseases.

Authors:  E Toubi
Journal:  Clin Rev Allergy Immunol       Date:  2008-06       Impact factor: 8.667

Review 4.  Treg cells in autoimmunity: from identification to Treg-based therapies.

Authors:  Lisa Göschl; Clemens Scheinecker; Michael Bonelli
Journal:  Semin Immunopathol       Date:  2019-04-05       Impact factor: 9.623

5.  GARP Dampens Cancer Immunity by Sustaining Function and Accumulation of Regulatory T Cells in the Colon.

Authors:  Mohammad Salem; Caroline Wallace; Maria Velegraki; Anqi Li; Ephraim Ansa-Addo; Alessandra Metelli; Hyunwoo Kwon; Brian Riesenberg; Bill Wu; Yongliang Zhang; Silvia Guglietta; Shaoli Sun; Bei Liu; Zihai Li
Journal:  Cancer Res       Date:  2019-01-23       Impact factor: 12.701

6.  Engagement of SLAMF3 enhances CD4+ T-cell sensitivity to IL-2 and favors regulatory T-cell polarization in systemic lupus erythematosus.

Authors:  Denis Comte; Maria P Karampetsou; Katalin Kis-Toth; Nobuya Yoshida; Sean J Bradley; Masayuki Mizui; Michihito Kono; Julie R Solomon; Vasileios C Kyttaris; George C Tsokos
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-01       Impact factor: 11.205

7.  The Role of the Transcription Factor Ets1 in Lupus and Other Autoimmune Diseases.

Authors:  Lee Ann Garrett-Sinha; Alyssa Kearly; Anne B Satterthwaite
Journal:  Crit Rev Immunol       Date:  2016       Impact factor: 2.214

Review 8.  Empowering Regulatory T Cells in Autoimmunity.

Authors:  Isaac R Kasper; Sokratis A Apostolidis; Amir Sharabi; George C Tsokos
Journal:  Trends Mol Med       Date:  2016-07-25       Impact factor: 11.951

Review 9.  [Regulatory T-cells in systemic lupus erythematosus. IL-2 is decisive for loss of tolerance].

Authors:  K Ohl; K Tenbrock
Journal:  Z Rheumatol       Date:  2016-04       Impact factor: 1.372

10.  Subpopulations of regulatory T cells in rheumatoid arthritis, systemic lupus erythematosus, and Behcet's disease.

Authors:  Jae-Ryong Kim; Jin-Nyeong Chae; Sang-Hyon Kim; Jung-Sook Ha
Journal:  J Korean Med Sci       Date:  2012-08-22       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.